CN103813784A - 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统 - Google Patents

控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统 Download PDF

Info

Publication number
CN103813784A
CN103813784A CN201280035162.8A CN201280035162A CN103813784A CN 103813784 A CN103813784 A CN 103813784A CN 201280035162 A CN201280035162 A CN 201280035162A CN 103813784 A CN103813784 A CN 103813784A
Authority
CN
China
Prior art keywords
testosterone
gel
intranasal
testosterone gel
intranasal testosterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280035162.8A
Other languages
English (en)
Chinese (zh)
Inventor
W·克雷普聂
S·福加尔蒂
W·奥别瑞吉尔
P·J·P·M·梅斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aiseersi Pharmaceutical Co Ltd
Original Assignee
Trimel Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimel Pharmaceuticals Corp filed Critical Trimel Pharmaceuticals Corp
Priority to CN201910982324.2A priority Critical patent/CN110613679A/zh
Publication of CN103813784A publication Critical patent/CN103813784A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201280035162.8A 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统 Pending CN103813784A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910982324.2A CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US61/486,324 2011-05-15
US201161486634P 2011-05-16 2011-05-16
US61/486,634 2011-05-16
PCT/IB2012/001127 WO2012156822A1 (en) 2011-05-15 2012-05-15 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910982324.2A Division CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统

Publications (1)

Publication Number Publication Date
CN103813784A true CN103813784A (zh) 2014-05-21

Family

ID=46579248

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201280035162.8A Pending CN103813784A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统
CN201811198846.5A Active CN109481394B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途
CN201280035150.5A Expired - Fee Related CN103796636B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途
CN201910982324.2A Pending CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201811198846.5A Active CN109481394B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途
CN201280035150.5A Expired - Fee Related CN103796636B (zh) 2011-05-15 2012-05-15 鼻内睾酮生物粘合性凝胶制剂及其治疗男性性腺功能减退症的用途
CN201910982324.2A Pending CN110613679A (zh) 2011-05-15 2012-05-15 控释鼻腔睾酮凝胶、用于经鼻给药的方法和预充式多剂量施药器系统

Country Status (16)

Country Link
EP (3) EP3977982A1 (enExample)
JP (9) JP2014513716A (enExample)
KR (10) KR20210135003A (enExample)
CN (4) CN103813784A (enExample)
AR (2) AR089553A1 (enExample)
AU (11) AU2012257492A1 (enExample)
BR (2) BR112013029336B1 (enExample)
CA (3) CA2836398C (enExample)
DK (1) DK2714006T3 (enExample)
EA (1) EA201391701A1 (enExample)
ES (1) ES2859784T3 (enExample)
IL (2) IL229401A0 (enExample)
MX (4) MX374398B (enExample)
PL (1) PL2714006T4 (enExample)
WO (2) WO2012156822A1 (enExample)
ZA (2) ZA201309265B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108771622A (zh) * 2018-07-11 2018-11-09 尹振图 一种自闭式针形滴嘴及眼药水瓶
CN110461340A (zh) * 2017-01-20 2019-11-15 马特恩制药股份公司 用于降低暴露于空气污染物的风险的鼻用药物组合物
CN111386119A (zh) * 2017-11-27 2020-07-07 Aska制药株式会社 粉末鼻腔给药制剂
TWI790204B (zh) * 2016-06-02 2023-01-21 加拿大商阿爾宙斯製藥有限公司 鼻用大麻素組成物

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AU2012257492A1 (en) * 2011-05-15 2013-12-19 Acerus Pharmaceuticals Srl Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
WO2014076569A2 (en) * 2012-11-14 2014-05-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
WO2015054213A1 (en) * 2013-10-07 2015-04-16 Wotton Paul K Hematocrit modulation through needle assisted jet injection of testosterone
WO2015127012A1 (en) 2014-02-19 2015-08-27 Wotton Paul K Needle assisted jet injection administration of testosterone compositions
WO2015179782A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
TW201636045A (zh) * 2015-01-28 2016-10-16 波美西恩製藥有限責任公司 組成物、促進或增強受試者之局部毛髮飽滿度及厚度或毛髮生長之方法、包括該組成物之套組及裝置
US10219894B2 (en) * 2015-06-29 2019-03-05 480 Biomedical, Inc. Implantable scaffolds for treatment of sinusitis
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
WO2017120492A1 (en) * 2016-01-07 2017-07-13 Viramal Limited Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
EP3448466A1 (en) 2016-04-25 2019-03-06 Koska Family Ltd. Medical delivery system
CA3026041A1 (en) * 2016-06-03 2017-12-07 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
CN110999431B (zh) * 2017-06-17 2022-04-05 Lg电子株式会社 用于在无线通信系统中注册终端的方法及其设备
KR102639913B1 (ko) 2017-11-17 2024-02-23 코스카 패밀리 리미티드 유체 전달 매니폴드를 위한 시스템 및 방법
JP2021512868A (ja) 2018-02-02 2021-05-20 エイセルス バイオファーマ インコーポレイテッド テストステロン療法の方法
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CA3117842A1 (en) 2018-10-26 2020-04-30 Viramal Limited Mucoadhesive gel composition
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
WO2020118437A1 (en) * 2018-12-14 2020-06-18 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
US20240009149A1 (en) * 2020-11-19 2024-01-11 Acousia Therapeutics Gmbh Non-aqueous gel composition
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133352A2 (en) * 2008-04-28 2009-11-05 Diurnal Limited Lipid composition
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
ATE418988T1 (de) * 1997-11-10 2009-01-15 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde systeme mit testosteron
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
MXPA04003359A (es) * 2001-10-12 2004-11-29 Cns Corporated Gel nasal hidratante y dispositivo aplicador.
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
JP5619337B2 (ja) * 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
NZ555641A (en) * 2004-12-09 2010-10-29 Bayer Animal Health Gmbh Stabilisation of glucocorticoid esters with acids
WO2006128255A1 (en) * 2005-06-03 2006-12-07 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
JP5248510B2 (ja) 2006-10-04 2013-07-31 エム アンド ペー パテント アクツィエンゲゼルシャフト 神経伝達物質の鼻腔投与のための徐放性送達システム
AU2008231781B2 (en) * 2007-03-23 2012-09-20 Besins Healthcare Luxembourg Sarl Compositions and method for treating pediatric hypogonadism
WO2009037813A1 (ja) * 2007-09-20 2009-03-26 Shiseido Company, Ltd. 経皮吸収製剤
DK2949361T3 (en) * 2007-11-13 2017-07-03 Athenion Ag C-19 STEROIDS FOR CELLULITE TREATMENT
AU2012257492A1 (en) * 2011-05-15 2013-12-19 Acerus Pharmaceuticals Srl Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311707A1 (en) * 2003-11-11 2010-12-09 Claudia Mattern Controlled release delivery system for nasal applications and methods of treatment
WO2009133352A2 (en) * 2008-04-28 2009-11-05 Diurnal Limited Lipid composition

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI790204B (zh) * 2016-06-02 2023-01-21 加拿大商阿爾宙斯製藥有限公司 鼻用大麻素組成物
CN110461340A (zh) * 2017-01-20 2019-11-15 马特恩制药股份公司 用于降低暴露于空气污染物的风险的鼻用药物组合物
CN111386119A (zh) * 2017-11-27 2020-07-07 Aska制药株式会社 粉末鼻腔给药制剂
CN108771622A (zh) * 2018-07-11 2018-11-09 尹振图 一种自闭式针形滴嘴及眼药水瓶
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶

Also Published As

Publication number Publication date
KR102568894B1 (ko) 2023-08-21
AU2017203470A1 (en) 2017-06-22
AU2024216312A1 (en) 2024-10-24
EP2714006A1 (en) 2014-04-09
IL229400A0 (en) 2014-01-30
JP2017160204A (ja) 2017-09-14
AU2020267162A1 (en) 2020-12-03
AU2020210227A1 (en) 2020-08-20
AU2019201618A1 (en) 2019-04-18
AU2017204182A1 (en) 2017-07-20
AR089553A1 (es) 2014-09-03
KR20140045400A (ko) 2014-04-16
MX2019003340A (es) 2019-07-04
MX2020008599A (es) 2022-08-31
CA3034552C (en) 2023-02-07
CN103796636A (zh) 2014-05-14
CA2836398A1 (en) 2012-11-22
PL2714006T3 (pl) 2021-08-16
AU2012257490A1 (en) 2013-12-19
KR20210135003A (ko) 2021-11-11
JP2018199701A (ja) 2018-12-20
JP2022105175A (ja) 2022-07-12
JP6152092B2 (ja) 2017-06-28
BR112013029332A2 (pt) 2021-06-01
WO2012156822A1 (en) 2012-11-22
PL2714006T4 (pl) 2021-08-16
KR20240162608A (ko) 2024-11-15
DK2714006T3 (da) 2021-03-15
BR112013029336A2 (pt) 2020-08-11
JP2021001206A (ja) 2021-01-07
AU2019203067A1 (en) 2019-05-23
EP2709588B1 (en) 2021-08-25
CA2836398C (en) 2021-12-14
WO2012156820A9 (en) 2014-02-20
BR112013029336B1 (pt) 2021-11-30
CA2836405A1 (en) 2012-11-22
MX2013013369A (es) 2014-10-17
KR20200118228A (ko) 2020-10-14
KR20210029849A (ko) 2021-03-16
IL229401A0 (en) 2014-01-30
AR086409A1 (es) 2013-12-11
JP7017254B2 (ja) 2022-02-08
JP6594924B2 (ja) 2019-10-23
JP2014515038A (ja) 2014-06-26
ZA201309265B (en) 2016-01-27
JP2014513716A (ja) 2014-06-05
MX2013013388A (es) 2014-09-15
EA201391701A1 (ru) 2014-04-30
MX374398B (es) 2025-03-06
JP2020079257A (ja) 2020-05-28
KR102088038B1 (ko) 2020-03-13
CA3034552A1 (en) 2012-11-22
KR20140033408A (ko) 2014-03-18
CN109481394B (zh) 2023-05-05
AU2022202402A1 (en) 2022-05-12
MX395212B (es) 2025-03-21
AU2019203400A1 (en) 2019-08-01
JP2020073469A (ja) 2020-05-14
CA2836405C (en) 2021-09-07
KR20200028503A (ko) 2020-03-16
KR20190006194A (ko) 2019-01-17
WO2012156820A1 (en) 2012-11-22
CN110613679A (zh) 2019-12-27
EP3977982A1 (en) 2022-04-06
ES2859784T3 (es) 2021-10-04
ZA201309264B (en) 2015-09-30
AU2012257492A1 (en) 2013-12-19
JP2022078222A (ja) 2022-05-24
KR20190117803A (ko) 2019-10-16
AU2020267162B2 (en) 2022-06-09
KR20230041081A (ko) 2023-03-23
CN103796636B (zh) 2019-04-05
EP2709588A1 (en) 2014-03-26
CN109481394A (zh) 2019-03-19
EP2714006B1 (en) 2020-12-09
MX363561B (es) 2019-03-27

Similar Documents

Publication Publication Date Title
US20250064831A1 (en) Controlled release topical testosterone formulations and methods
JP7017254B2 (ja) 経鼻投与のための徐放テストステロン鼻腔内ゲル、方法および複数回用量プレフィルアプリケーターシステム
US20150290217A1 (en) Male testosterone titration methods, male intranasal testosterone bio-adhesive gel formulations and use thereof for treating hypogonadism and trt
US20240316063A1 (en) Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
HK40018181A (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
HK1196261B (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
HK1263036A1 (en) Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160108

Address after: Barbados Christchurch District

Applicant after: Aiseersi Pharmaceutical Co. Ltd.

Address before: Barbados Christchurch District

Applicant before: TRIMEL PHARMACEUTICALS SRL

RJ01 Rejection of invention patent application after publication

Application publication date: 20140521

RJ01 Rejection of invention patent application after publication